‹ ›
MYP_089667
← PREVIOUS NEXT → BACK
Basic Information
21(derived from HCV C5A)
Antimicrobial
Antiviral
Antiviral ▸ Anti-Hepatitis virus ▸ Anti-HCV
Antiviral ▸ Anti-HIV
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Antiviral ▸ Antiviral mechanism ▸ Viral release inhibition
Antiviral ▸ Virucidal activity
Binding / Molecular interaction ▸ Binding activity
Enzyme modulation ▸ Enzyme inhibition ▸ Syncytium formation inhibitor
Standard
18 amino acids
C106H157N23O28
Standard
Sequence
DWLKAFYDKVAEKLKEAF
Physicochemical Analysis
2201.52 Da
6.21
-0.24
-0.45
-0.0132
-0.50
0.63
-0.04
23.98
76.11
0.2222
6990.00
6990.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
847.32
-2.20
29.0
28.0
74.0
157.0
5.0
17.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0060009 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HCV Release inhibition
Hepatitis C virus (HCV) | Huh-7.5.1 cells
28 μM
IC50
Mammalian: 1.1 h; Yeast: 3 min; E. coli: >10 h
PaperA virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. | Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV. | Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. | DOI:10.1073/pnas.0712380105 | PMID:18287023 PMID18287023 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/18287023/
RECORD: Rec_0141595 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antimicrobial Antiviral
Evidence URLhttps://patents.google.com/patent/US5447915A/en PatentUS 5447915 A
RECORD: Rec_0142340 VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
Terminally blocked antiviral peptide
32630.0
Structure & Mods
synthetic linear peptide [Linear]
mixed L/D amino-acid peptide [Mixed]
Bio-Activity Profile
Antiviral Anti-HIV
HIV
PaperTerminally blocked antiviral peptides Evidence URLhttps://patents.google.com/patent/US5447915A/en PatentUS 5447915 A
RECORD: Rec_0199272 VERIFIED: YES
Provenance & Taxonomy
Hepatitis C virus [Virus]
Virus-derived peptide
3052230;0
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Virucidal
Hepatitis C virus (Viral membrane); Huh7
28 μM
RT-PCR
PaperA virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. | Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV. | Proc Natl Acad Sci U S A. 2008 | PMID:18287023 PMID18287023 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/18287023/
RECORD: Rec_0242714 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]
Apolipoprotein A-I
9606
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Fusion inhibitor Syncytium formation inhibitor
HeLa
20 μM
IC50
PaperApolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. PMID2170446 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/2170446/
1 2 NEXT LAST
Showing 5 records on this page · Page 1 of 2